Loading...

Emblem

TSXV:EMC
Snowflake Description

Excellent balance sheet with high growth potential.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
EMC
TSXV
CA$157M
Market Cap
  1. Home
  2. CA
  3. Pharmaceuticals & Biotech
Company description

Emblem Corp. produces, distributes, and sells medical cannabis and cannabis derivatives in Canada. The last earnings update was 62 days ago. More info.


Add to Portfolio Compare Print
  • Emblem has significant price volatility in the past 3 months.
EMC Share Price and Events
7 Day Returns
0%
TSXV:EMC
3.6%
CA Pharmaceuticals
2.2%
CA Market
1 Year Returns
-47.8%
TSXV:EMC
-31%
CA Pharmaceuticals
-9.3%
CA Market
EMC Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Emblem (EMC) 0% 37.9% 2.6% -47.8% - -
CA Pharmaceuticals 3.6% 38.2% -13.2% -31% 882.6% 11.3%
CA Market 2.2% 8.4% -2% -9.3% 23.2% 5.4%
1 Year Return vs Industry and Market
  • EMC underperformed the Pharmaceuticals industry which returned -31% over the past year.
  • EMC underperformed the Market in Canada which returned -9.3% over the past year.
Price Volatility
EMC
Industry
5yr Volatility vs Market

Value

 Is Emblem undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Emblem to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Emblem.

TSXV:EMC Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 3 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 18.1%
Perpetual Growth Rate 10-Year CA Government Bond Rate 1.9%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for TSXV:EMC
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year CA Govt Bond Rate 1.9%
Equity Risk Premium S&P Global 8.1%
Pharmaceuticals Unlevered Beta Simply Wall St/ S&P Global 2.51
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 2.513 (1 + (1- 26.5%) (15.68%))
2.802
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
2
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 1.95% + (2 * 8.05%)
18.05%

Discounted Cash Flow Calculation for TSXV:EMC using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Emblem is arrived at by discounting future cash flows to their present value using the 2 stage method. We use analyst's estimates of cash flows going forward 5 years for the 1st stage, the 2nd stage assumes the company grows at a stable rate into perpetuity.

TSXV:EMC DCF 1st Stage: Next 5 year cash flow forecast
2019 2020 2021 2022 2023
Levered FCF (CAD, Millions) -14.13 3.36 26.71 33.87 36.72
Source Analyst x2 Analyst x1 Analyst x1 Analyst x1 Analyst x1
Present Value
Discounted (@ 18.05%)
-11.97 2.41 16.23 17.44 16.02
Present value of next 5 years cash flows CA$40.12
TSXV:EMC DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2023 × (1 + g) ÷ (Discount Rate – g)
= CA$36.72 × (1 + 1.95%) ÷ (18.05% – 1.95%)
CA$232.45
Present Value of Terminal Value = Terminal Value ÷ (1 + r)5
= CA$232.45 ÷ (1 + 18.05%)5
CA$101.38
TSXV:EMC Total Equity Value
Calculation Result
Total Equity Value = Present value of next 5 years cash flows + Terminal Value
= CA$40.12 + CA$101.38
CA$141.50
Equity Value per Share
(CAD)
= Total value / Shares Outstanding
= CA$141.50 / 130.56
CA$1.08
TSXV:EMC Discount to Share Price
Calculation Result
Value per share (CAD) From above. CA$1.08
Current discount Discount to share price of CA$1.20
= -1 x (CA$1.20 - CA$1.08) / CA$1.08
-10.7%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

  • The current share price of Emblem is above its future cash flow value.
Often investors are willing to pay a premium for a company that has a high dividend or the potential for future growth.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Emblem's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Emblem's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
TSXV:EMC PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-09-30) in CAD CA$-0.22
TSXV:EMC Share Price ** TSXV (2019-01-18) in CAD CA$1.2
Canada Pharmaceuticals Industry PE Ratio Median Figure of 15 Publicly-Listed Pharmaceuticals Companies 28.41x
Canada Market PE Ratio Median Figure of 555 Publicly-Listed Companies 14.08x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Emblem.

TSXV:EMC PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= TSXV:EMC Share Price ÷ EPS (both in CAD)

= 1.2 ÷ -0.22

-5.52x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Emblem is loss making, we can't compare its value to the CA Pharmaceuticals industry average.
  • Emblem is loss making, we can't compare the value of its earnings to the Canada market.
Price based on expected Growth
Does Emblem's expected growth come at a high price?
Raw Data
TSXV:EMC PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -5.52x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 3 Analysts
127.9%per year
Canada Pharmaceuticals Industry PEG Ratio Median Figure of 11 Publicly-Listed Pharmaceuticals Companies 0.81x
Canada Market PEG Ratio Median Figure of 264 Publicly-Listed Companies 0.99x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Emblem, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Emblem's assets?
Raw Data
TSXV:EMC PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-09-30) in CAD CA$0.67
TSXV:EMC Share Price * TSXV (2019-01-18) in CAD CA$1.2
Canada Pharmaceuticals Industry PB Ratio Median Figure of 108 Publicly-Listed Pharmaceuticals Companies 3.13x
Canada Market PB Ratio Median Figure of 2,297 Publicly-Listed Companies 1.46x
TSXV:EMC PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= TSXV:EMC Share Price ÷ Book Value per Share (both in CAD)

= 1.2 ÷ 0.67

1.8x

* Primary Listing of Emblem.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Emblem is good value based on assets compared to the CA Pharmaceuticals industry average.
X
Value checks
We assess Emblem's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Pharmaceuticals industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Pharmaceuticals industry average (and greater than 0)? (1 check)
  5. Emblem has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Emblem expected to perform in the next 1 to 3 years based on estimates from 3 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
127.9%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Emblem expected to grow at an attractive rate?
  • Emblem's earnings growth is expected to exceed the low risk savings rate of 1.9%.
Growth vs Market Checks
  • Emblem's earnings growth is expected to exceed the Canada market average.
  • Emblem's revenue growth is expected to exceed the Canada market average.
Annual Growth Rates Comparison
Raw Data
TSXV:EMC Future Growth Rates Data Sources
Data Point Source Value (per year)
TSXV:EMC Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 3 Analysts 127.9%
TSXV:EMC Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 3 Analysts 39.6%
Canada Pharmaceuticals Industry Earnings Growth Rate Market Cap Weighted Average 77.1%
Canada Pharmaceuticals Industry Revenue Growth Rate Market Cap Weighted Average 51.8%
Canada Market Earnings Growth Rate Market Cap Weighted Average 14.2%
Canada Market Revenue Growth Rate Market Cap Weighted Average 7%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
TSXV:EMC Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 3 Analyst Estimates (S&P Global) See Below
All numbers in CAD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
TSXV:EMC Future Estimates Data
Date (Data in CAD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 233 1
2022-12-31 205 1
2021-12-31 175 1
2020-12-31 142 28 3
2019-12-31 67 -1 3
2018-12-31 8 -22 2
TSXV:EMC Past Financials Data
Date (Data in CAD Millions) Revenue Cash Flow Net Income *
2018-09-30 6 -28 -23
2018-06-30 4 -13 -15
2018-03-31 3 -11 -13
2017-12-31 3 -11 -12
2017-09-30 2 -11 -17
2017-06-30 2 -10 -20
2017-03-31 1 -7 -19
2016-12-31 0 -6 -17
2016-09-30 0 -10
2015-12-31 -3 -3

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Emblem's earnings are expected to grow significantly at over 20% yearly.
  • Emblem's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
TSXV:EMC Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 3 Analyst Estimates (S&P Global) See Below

All data from Emblem Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

TSXV:EMC Future Estimates Data
Date (Data in CAD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31
2020-12-31 0.17 0.20 0.14 2.00
2019-12-31 0.02 0.09 -0.02 3.00
2018-12-31 -0.17 -0.16 -0.17 2.00
TSXV:EMC Past Financials Data
Date (Data in CAD Millions) EPS *
2018-09-30 -0.22
2018-06-30 -0.15
2018-03-31 -0.14
2017-12-31 -0.14
2017-09-30 -0.19
2017-06-30 -0.29
2017-03-31 -0.37
2016-12-31 -0.44
2016-09-30 -0.38
2015-12-31 -0.17

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Emblem will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Emblem's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Canada market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Canada market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Emblem has a total score of 5/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Emblem performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Emblem's growth in the last year to its industry (Pharmaceuticals).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Emblem does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Emblem's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Emblem's 1-year growth to the CA Pharmaceuticals industry average as it is not currently profitable.
Earnings and Revenue History
Emblem's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Emblem Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

TSXV:EMC Past Revenue, Cash Flow and Net Income Data
Date (Data in CAD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-09-30 5.71 -23.32 13.61 0.44
2018-06-30 4.04 -15.28 11.94 0.42
2018-03-31 3.07 -13.44 11.12 0.46
2017-12-31 2.69 -12.10 10.22 0.47
2017-09-30 2.27 -17.06 8.65 0.40
2017-06-30 1.71 -19.78 6.99 0.52
2017-03-31 1.17 -18.52 5.05 0.66
2016-12-31 0.28 -17.39 3.60 0.71
2016-09-30 0.04 -9.90 1.56 1.18
2015-12-31 -3.43 1.50 0.56
2014-12-31 -2.49 0.25 0.14

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Emblem has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Emblem has efficiently used its assets last year compared to the CA Pharmaceuticals industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Emblem improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Emblem's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Pharmaceuticals industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Emblem has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Emblem's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Emblem's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Emblem is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Emblem's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Emblem's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • High level of physical assets or inventory.
  • Debt is covered by short term assets, assets are 2.8x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Emblem Company Filings, last reported 3 months ago.

TSXV:EMC Past Debt and Equity Data
Date (Data in CAD Millions) Total Equity Total Debt Cash & Short Term Investments
2018-09-30 81.87 24.57 57.00
2018-06-30 89.63 24.06 75.89
2018-03-31 93.21 23.57 83.77
2017-12-31 52.06 16.23 37.75
2017-09-30 38.17 5.37 16.63
2017-06-30 40.25 5.36 23.66
2017-03-31 42.56 5.35 36.52
2016-12-31 29.61 5.34 26.20
2016-09-30 8.25 5.30 4.64
2015-12-31 -3.28 12.37 1.24
2014-12-31 -1.09 7.09 5.49
  • Emblem's level of debt (30%) compared to net worth is satisfactory (less than 40%).
  • Unable to establish if Emblem's debt level has increased without past 5-year debt data.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Emblem has sufficient cash runway for more than 3 years based on current free cash flow.
  • Emblem has sufficient cash runway for more than 3 years if free cash flow continues to grow at historical rates of 26.3% each year.
X
Financial health checks
We assess Emblem's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Emblem has a total score of 5/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Emblem's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Emblem dividends.
If you bought CA$2,000 of Emblem shares you are expected to receive CA$0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Emblem's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Emblem's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
TSXV:EMC Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 3 Analyst Estimates (S&P Global) See Below
North America Pharmaceuticals Industry Average Dividend Yield Market Cap Weighted Average of 11 Stocks 2.7%
Canada Market Average Dividend Yield Market Cap Weighted Average of 328 Stocks 3.6%
Canada Minimum Threshold Dividend Yield 10th Percentile 1.2%
Canada Bottom 25% Dividend Yield 25th Percentile 2.2%
Canada Top 25% Dividend Yield 75th Percentile 6.1%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

TSXV:EMC Future Dividends Estimate Data
Date (Data in CA$) Dividend per Share (annual) Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31
2020-12-31
2019-12-31
2018-12-31

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Emblem has not reported any payouts.
  • Unable to verify if Emblem's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Emblem's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Emblem has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Emblem's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.2%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Emblem afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Emblem has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Emblem's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Nick Dean
COMPENSATION CA$840,666
TENURE AS CEO 1.1 years
CEO Bio

Mr. Nicholas Dean also known as Nick has been Chief Executive Officer and President of Emblem Corp. since December 1, 2017. Mr. Dean has more than 12 years of consumer marketing and leadership experience including extensive work with highly respected pharmaceutical and healthcare brands. He worked with KBS Canada, a fully integrated creative agency with offices in Toronto and Montreal, where he led KBS through two mergers and a number of substantial client wins, resulting in significant bottom and top-line growth. He has been a Director of Emblem Corp. since February 2018. Mr. Dean earned his MBA from the Richard Ivey School of Business and holds his Bachelor of Commerce Degree from McMaster University.

CEO Compensation
  • Insufficient data for Nick to compare compensation growth.
  • Nick's remuneration is higher than average for companies of similar size in Canada.
Management Team Tenure

Average tenure and age of the Emblem management team in years:

1
Average Tenure
45
Average Age
  • The average tenure for the Emblem management team is less than 2 years, this suggests a new team.
Management Team

Nick Dean

TITLE
CEO, President & Director
COMPENSATION
CA$841K
TENURE
1.1 yrs

Harvey Shapiro

TITLE
Vice President
COMPENSATION
CA$175K
AGE
73

Maxim Zavet

TITLE
Vice President
COMPENSATION
CA$175K
AGE
38
TENURE
2.1 yrs

John Stewart

TITLE
Advisory of Medical Division & Director
COMPENSATION
CA$90K
TENURE
0.2 yrs

Gordon Fox

TITLE
COMPENSATION
CA$191K
TENURE
0.9 yrs

Alex Stojanovic

TITLE
Chief Financial Officer
TENURE
1 yrs

Ethan Karayannopoulos

TITLE
Head of Investor Relations

Karyn Sullivan

TITLE
General Counsel & Secretary
TENURE
1 yrs

Maria Guest

TITLE
Chief Marketing Officer
TENURE
0.8 yrs

Wayne Kreppner

TITLE
President of Medical Division
AGE
45
TENURE
0.2 yrs
Board of Directors Tenure

Average tenure of the Emblem board of directors in years:

0.9
Average Tenure
  • The average tenure for the Emblem board of directors is less than 3 years, this suggests a new board.
Board of Directors

Don Milliard

TITLE
Chairman of the Board
AGE
70
TENURE
0.2 yrs

Nick Dean

TITLE
CEO, President & Director
COMPENSATION
CA$841K
TENURE
0.9 yrs

Terry Johnson

TITLE
Director
COMPENSATION
CA$513K
TENURE
2.1 yrs

Jeff Fineberg

TITLE
Director
COMPENSATION
CA$513K
TENURE
2.1 yrs

John Stewart

TITLE
Advisory of Medical Division & Director
COMPENSATION
CA$90K
TENURE
2.1 yrs

Loreto Grimaldi

TITLE
Director
TENURE
0.2 yrs

Connie Stefankiewicz

TITLE
Director
TENURE
0.2 yrs
Who owns this company?
Recent Insider Trading
  • Emblem insiders have only sold shares in the past 3 months.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (CA$) Value (CA$)
03. Nov 18 Sell John Stewart Individual 30. Oct 18 30. Oct 18 -200,000 CA$1.14 CA$-227,200
06. Jun 18 Buy Nicholas Dean Individual 04. Jun 18 06. Jun 18 30,000 CA$1.49 CA$44,481
21. Mar 18 Sell John Stewart Individual 16. Mar 18 16. Mar 18 -50,000 CA$1.43 CA$-71,500
02. Feb 18 Buy Terry Johnson Individual 02. Feb 18 02. Feb 18 48,780 CA$2.05 CA$99,999
X
Management checks
We assess Emblem's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Emblem has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

External News
Loading...
Simply Wall St News

What Kind Of Shareholder Owns Most Emblem Corp. (CVE:EMC) Stock?

Large companies usually have institutions as shareholders, and we usually see insiders owning shares in smaller companies. … Our analysis of the ownership of the company, below, shows that. … institutions own shares in the company

Simply Wall St -

When Will Emblem Corp (CVE:EMC) Become Profitable?

produces, distributes, and sells medical cannabis and cannabis derivatives in Canada. … The company’s loss has recently broadened since it announced a -CA$12.1m loss in the full financial year, compared to the latest trailing-twelve-month loss of -CA$23.3m, moving it further away from breakeven. … I’ve put together a brief outline of industry analyst expectations for EMC, its year of breakeven and its implied growth rate

Simply Wall St -

Is Emblem Corp's (CVE:EMC) Balance Sheet Strong Enough To Weather A Storm?

While small-cap stocks, such as Emblem Corp (CVE:EMC) with its market cap of CA$192m, are popular for their explosive growth, investors should also be aware of their balance sheet to judge whether the company can survive a downturn. … Evaluating financial health as part of your investment thesis is

Simply Wall St -

Emblem Corp (CVE:EMC) Is Expected To Breakeven

produces, distributes, and sells medical cannabis and cannabis derivatives in Canada. … The company’s loss has recently broadened since it announced a -CA$12.10m loss in the full financial year, compared to the latest trailing-twelve-month loss of -CA$13.44m, moving it further away from breakeven? … View our latest analysis for Emblem

Simply Wall St -

Are Emblem Corp's (CVE:EMC) Interest Costs Too High?

While small-cap stocks, such as Emblem Corp (CVE:EMC) with its market cap of CA$171.72m, are popular for their explosive growth, investors should also be aware of their balance sheet to judge whether the company can survive a downturn.

Simply Wall St -

Growth Stocks Investors Love

EMC’s forecasted bottom line growth is an exceptional triple-digit, driven by underlying sales, which is expected to more than double, over the next few years. … Since net income isn’t artificially inflated by one-off initiatives such as cost-cutting, we know this profit growth is more likely to be sustainable. … Since net income isn’t artificially inflated by one-off initiatives such as cost-cutting, we know this profit growth is more likely to be sustainable.

Simply Wall St -

Financially Strong And High Growth Stocks

AEZS is expected to deliver a buoyant earnings growth over the next couple of years of 36.84%, bolstered by a significant revenue which is expected to more than double. … XDC is expected to deliver a triple-digit high earnings growth over the next couple of years, bolstered by an equally impressive revenue growth of 71.62%. … TSX:XDC Future Profit Mar 24th 18 For more financially robust companies with high growth potential to enhance your portfolio, explore this interactive list of fast growing companies.

Simply Wall St -

Company Info

Map
Description

Emblem Corp. produces, distributes, and sells medical cannabis and cannabis derivatives in Canada. The company also operates medical cannabis education centers to provide education services for making informed decisions about medical cannabis treatment options to physicians and patients. In addition, it provides various accessories. Emblem Corp. has a strategic partnership with GreenSpace Brands to develop and commercialize cannabidiol infused health and beauty products. The company is headquartered in Toronto, Canada.

Details
Name: Emblem Corp.
EMC
Exchange: TSXV
Founded:
CA$156,676,068
130,563,390
Website: http://emblemcorp.com
Address: Emblem Corp.
36 York Mills Road,
Suite 500,
Toronto,
Ontario, M2P 2E9,
Canada
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
TSXV EMC New Common Shares TSX Venture Exchange CA CAD 06. Dec 2016
OTCPK EMMB.F New Common Shares Pink Sheets LLC US USD 06. Dec 2016
DB E0M New Common Shares Deutsche Boerse AG DE EUR 06. Dec 2016
Number of employees
Current staff
Staff numbers
74
Emblem employees.
Industry
Pharmaceuticals
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/01/21 00:43
End of day share price update: 2019/01/18 00:00
Last estimates confirmation: 2018/12/20
Last earnings filing: 2018/11/20
Last earnings reported: 2018/09/30
Last annual earnings reported: 2017/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.